CLAIMS

1. A pharmaceutical composition comprising a compound represented by formula (**I**)



(**I**)

or a pharmaceutically acceptable salt thereof wherein the pharmaceutical composition comprises one or more excipients, optionally wherein the compound has a purity of at least 90%.

2. The pharmaceutical composition of claim 1, wherein said compound is represented by formula (**III**).



(**III**)

3. A pharmaceutical composition of claim 2,

wherein said compound is in a crystalline state.

4. The pharmaceutical composition of claim 3, wherein the compound exhibits characteristic X-ray powder diffraction peaks at about 7.0° 2θ, about 8.1° 2θ, about 10.0° 2θ, about 12.0° 2θ, about 13.1° 2θ, about 14.1° 2θ, about 16.4° 2θ, about 18.4° 2θ, about 20.1° 2θ, about 21.0° 2θ, about 23.5° 2θ, and about 29.5° 2θ.

5. The pharmaceutical compositionof claim 3, wherein the compound exhibits ^{1}H nuclear magnetic resonance (NMR) peaks centered at about 1.1 ppm, about 3.3 ppm, about 4.9 ppm, about 5.4 ppm, about 7.1 ppm, about 7.7 ppm, about 7.9 ppm, and about 8.0 ppm.

6. The pharmaceutical compositionof claim 3, wherein the compound exhibits an endotherm at from about 145° C to about 147° C as measured by differential scanning calorimetry.

7. The pharmaceutical composition of claim 3, wherein the compound exhibits a weight loss of from about 0.2% to about 0.6% when heated from 25° C to 100° C as measured by thermogravimetric analysis.

8. The pharmaceutical composition of any one of claims 1-7 for use in treating or preventing preterm labor in a human patient, wherein a therapeutically effective amount of the pharmaceutical composition is to be administered to the patient.

9. The pharmaceutical composition for use in accordance with claim 8, wherein the patient is characterized by a gestational age of from about 24 weeks to about 34 weeks.

10. The pharmaceutical composition for use in accordance with claim 8 or 9, wherein the patient exhibits a reduction in the amplitude of uterine contractions following use.